Purdue Pharma’s Richard Sackler ignored OxyContin addiction concerns, new emails show
December 3, 2019Manufacturing and Production, Sales and Marketing Opiod, Purdue Pharma, Richard Sackler, opiod crisis
A recently exposed 1997 email chain shows Dr Richard Sackler, member of the billionaire founding family of Purdue Pharma, knew …
AstraZeneca sells US/Canada rights for Seroquel for $41 million to “focus on main therapy areas”
December 3, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, pharma
AstraZeneca has announced its intention to jettison the rights to two non-core drugs in the US and Canada in order …
Jeremy Corbyn writes Trump letter asking for reassurance over NHS in trade deal
December 3, 2019Manufacturing and Production Boris, Boris Johnson, Boris NHS, Jeremy Corbyn, Labour Party, NHS, Trump
Labour Party leader Jeremy Corbyn has written to US President Donald Trump demanding he confirm that he will not put …
Reagan-era FDA Commissioner Frank Young dies
December 3, 2019Manufacturing and Production FDA, FDA commissioner, Frank Young
Frank Young, FDA Commissioner from 1984-1989, died on 24 November. He was 88; his son, Jonathan, said the cause was …
Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash
December 3, 2019Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma
Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
December 2, 2019Sales and Marketing British pharmaceuticals, Dr Richard Corbett, apbi, appointments
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its new Chief Executive. He will …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
December 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma
Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …
FDA urged to investigate use of unapproved drug on prisoners
December 2, 2019Sales and Marketing FDA, Opiods, US Opiods, opiod crisis
The Louisiana Department of Public Safety and Corrections (LDPSC) and BioCorRx Inc are alleged to have collaborated in testing an …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Labour and Lib Dems make election pledge for wider access to HIV drug
December 2, 2019Sales and Marketing AIDS, Conservatives, HIV. HIV Drugs, Labour Party, Liberal Democrats, lib dems
The Labour Party and the Liberal Democrats have both pledged to roll out access to pre-exposure prophylaxis (PrEP) therapy for …
British pharmaceutical industry is threatened by Labour, says former Party health minister
December 2, 2019Sales and Marketing British pharmaceuticals, Election 2019, Jeremy Corbyn, Labour Party, NHS
A former Labour Party health minister has said that the British pharmaceutical industry is “under threat” from a Jeremy Corbyn …
Roche’s satralizumab shows promise at Phase 3 in neuromyelitis optica spectrum disorder
December 2, 2019Research and Development, Sales and Marketing Roche, pharma, satralizumab
Roche has presented new data on its interleukin-6 (IL-6) inhibitor satralizumab in the treatment of neuromyelitis optica spectrum disorder (NMOSD), …
Top Ten most popular articles on Pharmafile.com this week
November 29, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boris Johnson, Jeremy Corbyn, NHS, Opiod, US, opiod crisis
The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which …
Few in NHS trust tech firms handling patient data
November 29, 2019Medical Communications AI, Boris, Corbyn, NHS, NHS Brexit, johnson
Few in the NHS trust ‘big tech’ companies to handle patient data in a confidential manner, a recent YouGov poll …
Immupharma and Avion sign agreement for lupus drug Lupuzor
November 29, 2019Medical Communications Diseases, Lupus, Lupuzor, avion
Immupharma has signed a development agreement with Avion Pharmaceuticals to acquire the licensing rights for Lupuzor, a peptide therapeutic and …
Study shows widespread bribery in Indian pharmaceutical industry
November 29, 2019Medical Communications India, Indian Pharma, Modi, bribery
A recent report by the Support for Advocacy and Training to Health Initiatives (Sathi) revealed the widespread use of bribes …
FDA gives priority review for AstraZeneca’s Imfinzi
November 29, 2019Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer
The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Majority of British people worried about the fate of the NHS in post-Brexit US trade deal, survey reveals
November 28, 2019Medical Communications Boris Johnson, Jeremy Corbyn, NHS, Trump, brexit, european union
In a newly released survey on “Over-The-Counter (OTC) and Pharma 2019”, by the business data platform Statista, 55% of people …
Drugmakers cut prices by 61% to get on Chinese reimbursement list
November 28, 2019Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding
AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
